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Ciprofloxacin Is Actively Transported across Bronchial Lung Epithelial
Cells Using a Calu-3 Air Interface Cell Model
Hui Xin Ong,a,b Daniela Traini,a,b Mary Bebawy,c Paul M. Younga,b
Respiratory Technology, Woolcock Institute of Medical Research, Sydney, NSW, Australiaa; Discipline of Pharmacology, Sydney Medical School, University of Sydney, NSW,
Australiab; School of Pharmacy, Graduate School of Health, University of Technology Sydney, Broadway, NSW, Australiac
Ciprofloxacin is a well-established broad-spectrum fluoroquinolone antibiotic that penetrates well into the lung tissues; still, the
mechanisms of its transepithelial transport are unknown. The contributions of specific transporters, including multidrug efflux
transporters, organic cation transporters, and organic anion-transporting polypeptide transporters, to the uptake of ciprofloxa-
cin were investigated in vitro using an air interface bronchial epithelial model. Our results demonstrate that ciprofloxacin is
subject to predominantly active influx and a slight efflux component.
Ciprofloxacin is an established broad-spectrum fluoroquin-olone antibiotic indicated for the treatment of exacerbations
of respiratory tract infection in its oral and parenteral dosage
forms. It has been shown to be particularly effective against Pseu-
domonas aeruginosa, which is amajor cause of the severe decline in
lung function in patients with cystic fibrosis and bronchiectasis
(1–4). In general, the pharmacokinetics of fluoroquinolones in
different tissues have beenwell characterized, withmultiple trans-
porters being implicated in contributing to the drug’s deposition
in the liver, kidney, and intestinal tract.
In the respiratory tract, studies have demonstrated that cipro-
floxacin penetrates into the lung tissue through transepithelial
permeation across the bronchial epithelium (5–7). Unlike amin-
oglycosides and -lactams, which are excluded from intracellular
infections, fluoroquinolones are efficient in treating respiratory
tract infections (RTIs) caused by both intracellular and extracel-
lular pathogens (8). Hence, inhalation could potentially be the
preferred mode of delivery for this drug, as it would ensure direct
deposition of the medication to the site of action and, at the same
time, could reduce systemic toxicity. However, there is a lack of
information regarding themechanisms of ciprofloxacin transport
across the lung epithelium.
At present, tobramycin (TOBI) and aztreonam (Cayston) are
the only inhaled antibiotic treatments approved by the Food and
Drug Administration (FDA). Although there is no regulatory ap-
proval for inhaled ciprofloxacin, current evidence demonstrates
that it has the potential to be developed into an effective inhaled
medication for RTIs (9–12).
To date, pulmonary transporters relevant to drug transport
comprise three main groups: the ATP-binding cassette (ABC) ef-
flux transporters (i.e., P-glycoprotein [P-gp] andmultidrug resis-
tance-associated protein 1 [MRP-1]); the solute carrier (SLC)
transporters, which include members of the organic cation trans-
porters (OCTs) and organic anion transporters (OATs); and fi-
nally, the organic anion-transporting polypeptides (OATPs) (13,
14). Very little is known about the potential impact of these lung
epithelial membrane transporters on the absorption and disposi-
tion of antibiotics that are inhaled, which could alter their reten-
tion and accumulation within the lung, resulting in either subop-
timal concentrations or toxicity. Thus, by understanding the
mechanisms for ciprofloxacin transport across the lung epithe-
lium, it may be possible to better predict the extent of pulmonary
disposition required for optimal bacterial killing efficacy.
The aim of this study was to investigate the cellular mecha-
nisms of ciprofloxacin transepithelial transport across human
bronchiolar epithelial cells and examine the possible interactions
of specific lung transporters on uptake and efflux. The air interface
Calu-3 cell model has previously been established by us as an
effective and predictive in vitromodel for the study of drug deliv-
ery and toxicology (7, 15–18) and was thus used to study the
mechanisms of ciprofloxacin transport. This model has physio-
logical characteristics that are similar to those of native pulmonary
epithelium in terms of differentiation, mucus production, trans-
epithelial resistance, morphology, and, importantly, transporter
expression (13, 17, 19).
Drug transport across a functional epithelium cell system
could occur via the nonselective diffusion-driven paracellular
route (i.e., a route with tight junctions and lateral interspaces) or
via a transcellular route either by passive diffusion or mediated by
specific transporters. Ciprofloxacin has been known to cross the
epithelium primarily via transcellular routes, and this transport
appears to be mediated by simple diffusion processes and facili-
tatedmechanisms (7).However, the specific transporters involved
in ciprofloxacin absorption have not yet been identified. To fur-
ther understand the contribution of active transport processes in
ciprofloxacin uptake across the lung epithelium, selective trans-
port inhibitors were used to identify the ciprofloxacin transport-
ers involved. Specifically, efflux transporters, including P-gp and
the multidrug resistance-associated proteins (MRPs), together
with influx transporters, including OCTs and OATPs, were stud-
ied. These transporters have been detected in healthy human lung
cells and Calu-3 cells (13, 20–22).
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Materials. Calu-3 cells were purchased from the American Type Culture
Collection (ATCC; Manassas, VA). Nonessential amino acid solution,
dimethyl sulfoxide (DMSO), tetraethyl ammonium chloride (TEA), ve-
rapamil HCl, ciprofloxacin, probenecid, and fluorescein sodium (flu-Na)
were purchased from Sigma-Aldrich (Sydney, Australia). Other cell cul-
ture reagents, including trypsin-EDTA solution (2.5 g/liter trypsin, 0.5
g/liter EDTA), Dulbecco’s modified Eagle’s medium (DMEM; without
phenol red and L-glutamine but including sodium bicarbonate and 15
mM HEPES), trypan blue solution (0.4%, wt/vol), phosphate-buffered
saline (PBS), L-glutamine solution (200 mM), fetal bovine serum (FBS),
andHanks’ balanced salt solution (HBSS), were obtained from Invitrogen
(Australia). PSC833 was purchased from Tocris Bioscience (Bristol,
United Kingdom). Transwell cell culture inserts (0.33 cm2 polyester,
0.4-m pore size) were purchased from Corning Costar (Lowell, MA),
and all other sterile culture plasticware was from Sarstedt (Adelaide, Aus-
tralia). All solvents used were of analytical grade and were supplied by
Biolab (Victoria, Australia).
Cell culture. The Calu-3 cell line (HTB-55) was purchased from
ATCC.Cells between passages 35 and 42weremaintained in tissue culture
flasks of 75 cm2 and cultured in prewarmed DMEM supplemented with
10% (vol/vol) fetal bovine serum, 1% (vol/vol) nonessential amino acid
solution, and 1% (vol/vol) L-glutamine solution. Cells were incubated at
37°C in 5% CO2 and 95% humidity until confluence was reached. Me-
diumwas exchanged every 2 to 3 days, and the cells were passaged weekly,
according to ATCC-recommended guidelines.
Calu-3 cells were grown at the air interface to allow monolayer differ-
entiation, and experiments were performed between days 11 and 14.
These conditions have previously been established byHaghi et al. (17) and
Grainger et al. (19). Briefly, cells were seeded at a density of 5  105
cells/cm2 on 24 transwell cell culture inserts. The cells were introduced in
100 l medium onto the apical surface of the transwell, and 500 l me-
diumwas added to the basolateral chamber. Subsequently, themedium in
the apical chamber was removed after 24 h, and medium was replaced
only in the basolateral chambers every 2 to 3 days.
Transport inhibition studies. Selective pharmacological inhibitors
were used to inhibit specific transporters and assess their contribution
toward ciprofloxacin transport. Transport experiments were conducted
in both the apical-to-basolateral (A-B) and basolateral-to-apical (B-A)
directions. Solutions of ciprofloxacin (0.1 mM) were prepared in HBSS
with or without the presence of the following inhibitors at the indicated
concentrations: TEA (5 mM), estrone-3-sulfate (5 mM), verapamil hy-
drochloride (10 M), PSC833 (3 M), and probenecid (1 mM). Drug
concentrations are based on previous literature to ensure effective inhibi-
tion, simultaneously taking into consideration the solubility and toxicity
of the inhibitors (23–25). Cells were preequilibrated for 1 h with the re-
spective inhibitors. Upon initiation of the transport studies, the volume of
the donor compartmentwas replacedwith the test solution (ciprofloxacin
with the respective inhibitors). Samples from the acceptor compartment
were taken every 30min over a 4-h period and subsequently replaced with
fresh inhibitor solutions. Control studies with ciprofloxacin (0.1 mM)
alone were performed concurrently. Samples were analyzed using high-
performance liquid chromatography (HPLC). Analyses were performed
in triplicate.
Ciprofloxacin analysis. Ciprofloxacin was quantified using HPLC.
This was achieved using a Shimadzu Prominence liquid chromatography
system equipped with an SPD-20A UV-visible detector, an LC-20AT liq-
uid chromatograph, an SIL-20A HT autosampler (Shimadzu Corpora-
tion, Japan), and a NovaPak C18 column (5 m, 150 by 3.9 mm). The
mobile phase was a mixture of methanol and 0.1 M sodium dihydrogen
phosphate at a ratio of 30:70 (vol/vol), with the pH adjusted to 3.35 with
phosphoric acid. HPLC was set according to the following conditions: a
detection wavelength of 275 nm, a flow rate of 1.0 ml/min, and an injec-
tion volume of 100 l. Linearity was obtained between 0.1 and 50 g/ml
(R2 0.99), and the retention time was 7.85 min.
Calu-3 epithelial cell integrity. The flu-Na (molecular mass, 0.367
kDa) uptake experiments were performed tomeasure the barrier integrity
of the Calu-3 epithelial cell after the transport experiments, as previously
described (17). Flu-Na was first dissolved in prewarmed HBSS to a con-
centration of 2.5 mg/ml, and to initiate the experiment, 200 l of this
solution was added to the apical surface of the cells. Six hundred microli-
ters of HBSS was placed in the basolateral chamber, where 100 l of
sample was drawn from the chamber every 20 min over a 1-h period. An
equal volume of fresh HBSS was added to replace the sample that was
withdrawn. Samples were placed in a black, 96-well plate, and fluores-
cence readings were taken using a POLARstar Optima fluorescence plate
reader (BMG Labtech, Offenburg, Germany) with excitation and emis-
sion wavelength settings of 485 and 520 nm, respectively.
Cell viability. The cytotoxicity profiles of ciprofloxacin in the pres-
ence and absence of the transport inhibitors were assessed using a Cell-
Titer 96 AQueous One Solution cell proliferation assay (Promega). Calu-3
cells were seeded into sterile 96-well microtiter plates at a density of 5
104 cells/well and were left overnight to allow cell attachment. Cells were
treated with increasing concentrations (up to 50 mM) of ciprofloxacin
and other transporter inhibitors in complete DMEM at a final volume of
200l. Control wells contained cells andmediumwithout the addition of
drugs. Plates were incubated at 37°C in 5%CO2 and 95% humidity for 72
h. The cells were analyzed for viability following the addition of 20 l of
AQueous One Solution to each well and incubation for 3 h at 37°C in 5%
CO2 and 95% humidity. The absorbance of the wells was measured at 490
nm using a fluorescence plate reader (POLARstar Optima; BMG Labtech,
Offenburg, Germany). The cell viability (in percent) was calculated on the
basis of the following formula: (average absorbance of treated cells/aver-
age absorbance of control cells) 100.
Data analysis. The apparent permeability coefficient (Papp) across
Calu-3 epithelial cells was calculated using the following equation: (V/
AC0)(dC/dt), where V is the volume of solution in the basolateral cham-
ber,A is the surface area of the transwell membrane (cm2),C0 is the initial
drug concentration in the apical compartment (g/ml), and dC/dt is the
flux (rate of change in cumulative mass transport, where C is concentra-
tion and t is time) of flu-Na.
All results are expressed as means  standard deviations of at least
three separate determinations. To determine significance between groups
and the control, the unpaired 2-tailed t test was performed (quoted at the
level of P 0.05).
RESULTS AND DISCUSSION
The current results indicate that active transport mechanisms are
involved in ciprofloxacin transepithelial absorption. Figure 1
presents a schematic diagram of the Calu-3 cells, showing the ex-
pression and localization of the various types of transporters (Fig.
1A), and a list of the selective inhibitors and the drug transporters
that they inhibit (Fig. 1B).
The apparent permeability coefficient (Papp) of ciprofloxacin
over 4 h in the presence and absence of transporter inhibitors is
shown in Fig. 2 and Table 1. There is an evident dissymmetry of
Papp values in the secretory (B-A) and absorptive (A-B) directions
and an active net absorption of ciprofloxacin across the Calu-3
epithelial cells. The results indicate for the first time that influx
transporters, the OCTs, and, more specifically, OATPs are in-
volved in the absorption of ciprofloxacin across the lung epithe-
lium. The presence of TEA (OCT competitive substrate) (20) and
estrone-3-sulfate (OATP2B1 inhibitor) (25) significantly reduces
the absorption of ciprofloxacin in the apical to the basolateral
direction. Additionally, these inhibitors reduce the net ciprofloxa-
cin absorption, which is consistent for a carrier-mediated process
in part contributing to the absorption of ciprofloxacin across the
lung epithelia. This is not surprising, as ciprofloxacin is a zwitter-
Ong et al.











ion at physiological pH (26), and thus, solute carriers are expected
to contribute to the absorption, distribution, and elimination of
ionic compounds.
For the efflux pathways, verapamil has been known to inhibit
both P-gp and MRPs (24). In the presence of the inhibitor, the
Papp of ciprofloxacin was significantly increased and decreased in
both the absorption and secretory pathways, respectively. This is
indicative of the presence of these efflux transporters. However,
the low permeation of ciprofloxacin only in the secretory direc-
tion suggests that these efflux transporters have only aminor con-
tribution to the transport of ciprofloxacin. The significantly
higher permeation of ciprofloxacin could have been contributed
by the influence of verapamil on the physical properties of lipid
bilayers by altering the membrane fluidity and subsequently in-
creasing membrane permeability, in addition to its modulating
effects on these ABC transporters (27–29). Additionally, other
studies have also demonstrated that verapamil may also have an
effect on uptake carriers such as OCTs (30, 31), which could be
explored in the future.
To further investigate the specific transporter involved,
PSC833 was selected since it is a highly effective and relatively
more specific inhibitor of P-gp (24) but did not significantly affect
the absorption of ciprofloxacin in the A-B direction. Hence, there
are only slight contributions of P-gp to ciprofloxacin efflux. In
comparison, the presence of probenecid, a known MRP trans-
porter inhibitor (32, 33), significantly decreased the permeation of
ciprofloxacin in both the absorptive and secretory directions. In
addition, statistical analysis of the ciprofloxacin Papp in the pres-
ence of probenecid showedno significant difference in the absorp-
tive (A-B) and secretory (B-A) directions (P  0.07), suggesting
MRP involvement in the active transport of ciprofloxacin across
the Calu-3 lung epithelial model. However, there is conflicting
evidence suggesting that probenecid may also interact with not
onlyMRPs but also OAT and OATP due to its anionic nature (34,
35). Hence, the involvement of these influx transporters could
also contribute to the decrease in ciprofloxacin permeation when
probenecid is used.
Currently, there are only a few studies on the role of transport-
ers and the transportmechanisms for ciprofloxacin in organs such
as the intestine and liver but none on their role in the lung. In
terms of active influx transport, a study byHirano et al. (36) found
that ciprofloxacin inhibits L-carnitine transport across a placental
cell line through the inhibition of the OCTN2 transporters. This
was subsequently proposed to be the potential mechanism of its
toxicity toward fetuses, as L-carnitine has an important role in
generating energy in the placenta for the developing fetus. On the
other hand, earlier studies have shown preferential efflux of cip-
rofloxacin in Caco-2 cells, which may explain the transintestinal
elimination of ciprofloxacin (37, 38). However, P-gp was ex-
cluded as a cause of its secretion, and it was suggested that the
transport mechanism is sensitive to organic anion exchange and
verapamil (39). Similar findings were observed in kidney epithe-
lial cells (40), and this is in good agreement with findings in the
current study.
On the basis of the results, both active and passive transport
contributed to the uptake of ciprofloxacin through the pulmonary
epithelial cells. This has significant implicationswith respect to the
delivery of ciprofloxacin antibiotics for treatment of RTIs. The
low permeation of ciprofloxacin through the secretory pathway
suggests that high doses of orally or intravenously administered
ciprofloxacin would be required to ensure that sufficient concen-
trations of antibiotics reach the lungs via systemic absorption,
which would result in potential toxicity. Hence, an inhalation
route to treat RTIswould be favorable. Conversely, the high rate of
FIG 2 Papp of 0.1 mM ciprofloxacin (Cipro) in both the A-B and B-A direc-
tions across Calu-3 epithelial cells. Data are presented asmeans SDs (n 3).
*, significantly different from ciprofloxacin in the A-B direction; #, signifi-
cantly different from ciprofloxacin in the B-A direction.
FIG 1 (A) Schematic diagram of Calu-3 epithelial cells showing the expression and localization of different transporters; (B) the different inhibitors used in this
study and the transporter proteins that they inhibit (13, 20, 24, 25, 32, 33).
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clearance of inhaled ciprofloxacin (10, 16) is due to the high per-
meation of this drug through the absorptive pathway. This was
evident in two recent studies looking at administration of cipro-
floxacin through the pulmonary and gastrointestinal routes in a
rat and mice, respectively (41, 42). Of note, the MIC for Pseu-
domonas aeruginosa was found to be between 0.25 and 1.0 g/ml
(10, 43). The study by Chono et al. (42) showed that a dose of
5,000 g/kg of body weight of ciprofloxacin intragastrically in-
stilled into the mice resulted in a ciprofloxacin level of 0.45g/ml
in the lungs at 30 min, indicative of its low permeation into lung
tissues. Conversely, a dose of 200g/kg ciprofloxacin intranasally
instilled into a rat resulted in approximately 18 g/ml of cipro-
floxacin in the epithelial lining fluid at 30 min after administra-
tion, which was much higher than the required MIC (41). Hence,
the inhalation route will be more favorable because it will provide
a high local concentration in the lung using lower doses of cipro-
floxacin and will avoid systemic exposure. However, this concen-
tration rapidly diminishes to half its initial concentration within 1
h, demonstrating its rapid clearance from the lungs. Formulation
strategies can therefore be directed toward increasing its residency
time in the lungs or enhancing penetration of ciprofloxacin into
the lung tissue. Moreover, drug-drug interaction could occur at
the lung level, resulting in a subsequent change in the ciprofloxa-
cin distribution when it is combined with other substrates or
modulators of the different transporters involved.
Fluorescein sodium (flu-Na) was used to assess paracellular
transport as a measure of Calu-3 epithelial cell integrity after the
transport experiments, and results obtainedwith flu-Nawere sub-
sequently compared to those obtained with the control. Cipro-
floxacin with and without the inhibitors had no detrimental ef-
fects on the integrity of the epithelial cells under the conditions or
time scale studied, as shown in the results of the flu-Na perme-
ation assay in Fig. 3. No significant difference was found between
the results for cells treated with ciprofloxacin and their respective
inhibitors and those for control cells (P  0.05). Additionally, a
toxicity assay was used to measure the viability of Calu-3 cells
(liquid interface model) exposed to increasing concentrations of
ciprofloxacin and other transport inhibitors over a 72-h treatment
period (Fig. 4). The viability of the cells was calculated with refer-
ence to that of untreated cells, where the average absorbance value
was normalized to 100% viability. Both ciprofloxacin and inhibi-
tors were found to be not toxic to the lung epithelial cells over the
concentration range used in this study, except for verapamil (50%
FIG 3 Transport of flu-Na across the Calu-3 epithelial cell layer after 4 h of
ciprofloxacin transport with the presence of various transport inhibitors
(mean SD, n 3).
TABLE 1 Papp of ciprofloxacin in both the A-B and B-A directions across Calu-3 epithelial cells
Inhibitor Concn (M)
Papp
a (cm · s1 [107])
Net absorptionb
(cm · s1 [107])A-B B-A
Control (ciprofloxacin base) 100 10.27 0.39 4.31 0.22 5.96
TEA 5,000 9.12 0.55c 4.15 0.26 4.96
Estrone-3-sulfate 5 3.22 0.16c 6.60 0.36d 3.38
Verapamil 10 34.15 5.22c 3.53 0.3d 30.62
PSC833 3 10.11 0.41 3.36 0.02d 6.75
Probenecid 1,000 1.60 0.21c 1.25 0.13d 0.53
a Data are presented as mean standard deviation (n 3).
b Net absorption is absorption in the A-B direction minus absorption in the B-A direction.
c Significantly different from ciprofloxacin in the A-B direction.
d Significantly different from ciprofloxacin in the B-A direction.
FIG 4 Cytotoxicity of ciprofloxacin, verapamil, and PSC833 (A) and TEA,
estrone-3-sulfate, and probenecid (B) for Calu-3 cells after 72 h (mean SD,
n 3).
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inhibitory concentration  14.12  1.15 M). Hence, the con-
centration of verapamil was limited to 10 M in the transport
study to prevent any cell toxicity. However, it needs to be noted
that the cytotoxicity experiments were performed over a 72-h pe-
riod, whereas the transport studies were performed over 4 h on air
interface Calu-3 cells, which have morphologies and biochemical
responses different from those of cells in liquid-covered cultures.
Nevertheless, the experiments demonstrate the range of drug con-
centrations that these cells could tolerate.
Conclusion. This study has clearly shown that ciprofloxacin is
a substrate for active transport in the air interface Calu-3 cell
model and suggests the involvement of OCTs, OATP2B1, and
MRPs as transporters. Importantly, this has implications with re-
spect to the delivery of ciprofloxacin antibiotics by inhalation
treatment and also possible drug-drug interactions. Hence, fur-
ther studies on expression levels and functional properties are
required to better understand the clinical relevance of these drug
transporter interactions.
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